Accuray (ARAY) to Release Earnings on Wednesday

Key Points

• Accuray (NASDAQ:ARAY) is expected to release its Q4 2025 earnings results on August 13th, forecasting earnings of $0.03 per share and revenue of $123.78 million.
• Shares of Accuray opened at $1.30, with a 12-month low of $1.14 and a high of $2.95, indicating volatility in its stock performance.
• Recently, Jane Street Group LLC significantly increased its stake in Accuray by 429.3%, owning approximately 64.08% of the company's stock held by institutional investors.

Accuray (NASDAQ:ARAY - Get Free Report) is projected to post its Q4 2025 quarterly earnings results after the market closes on Wednesday, August 13th. Analysts expect Accuray to post earnings of $0.03 per share and revenue of $123.78 million for the quarter.

Accuray Stock Performance

Shares of NASDAQ:ARAY opened at $1.30 on Wednesday. The business's 50 day moving average is $1.36 and its 200 day moving average is $1.67. Accuray has a 12-month low of $1.14 and a 12-month high of $2.95. The company has a quick ratio of 0.92, a current ratio of 1.64 and a debt-to-equity ratio of 3.35.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Accuray from a "hold" rating to a "buy" rating in a research note on Friday, May 30th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Accuray stock. Jane Street Group LLC raised its holdings in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 429.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 91,944 shares of the medical equipment provider's stock after purchasing an additional 74,574 shares during the period. Jane Street Group LLC owned approximately 0.09% of Accuray worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 64.08% of the company's stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.